Tanvir Bajwa

Aurora St. Luke's Medical Center, Milwaukee, Wisconsin, United States

Are you Tanvir Bajwa?

Claim your profile

Publications (87)511.22 Total impact

  • European Heart Journal – Cardiovascular Imaging 02/2015; DOI:10.1093/ehjci/jev016 · 2.65 Impact Factor
  • JACC Cardiovascular Interventions 02/2015; 8(2). DOI:10.1016/j.jcin.2014.12.010 · 7.44 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Access site hematomas and pseudoaneurysms are the most frequent complications of peripheral vascular intervention (PVI); however, their incidence and risk factors remain unclear.
    Circulation Cardiovascular Interventions 11/2014; DOI:10.1161/CIRCINTERVENTIONS.114.001306 · 6.98 Impact Factor
  • European Heart Journal – Cardiovascular Imaging 09/2014; 16(1). DOI:10.1093/ehjci/jeu161 · 2.65 Impact Factor
  • Tonga Nfor, Suhail Allaqaband, Tanvir Bajwa
    [Show abstract] [Hide abstract]
    ABSTRACT: Improvements in the design of endovascular devices and technical skill of interventionalists have opened new possibilities for patients with a wide range of peripheral vascular diseases (PVD). In lower extremity peripheral artery disease, percutaneous treatments have become the predominant revascularization strategy for simple and complex lesions. Newer generations of stents and drug-coated balloons have demonstrated strong potential in treatment of femoropopliteal and infrainguinal diseases. One of the most dramatic advances in the recent past has been endovascular repair of thoracic and abdominal aortic aneurysms, which has become the preferred approach in lieu of open surgical repair. Contemporary trials have established the safety and effectiveness of carotid stenting in selected patients with severe stenosis. Endovascular treatments for venous occlusive disease have long been underutilized, but their effectiveness is being increasingly recognized. This review will cover new endovascular procedures performed by interventional cardiologists for PVD.
    Current Problems in Cardiology 08/2014; DOI:10.1016/j.cpcardiol.2014.05.003 · 2.17 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background The EVEREST II (Endovascular Valve Edge-to-Edge REpair STudy) High-Risk registry and REALISM Continued Access Study High-Risk Arm are prospective registries of patients who received the MitraClip device (Abbott Vascular, Santa Clara, California) for mitral regurgitation (MR) in the United States. Objectives The purpose of this study was to report 12-month outcomes in high-risk patients treated with the percutaneous mitral valve edge-to-edge repair. Methods Patients with grades 3 to 4+ MR and a surgical mortality risk of ≥12%, based on the Society of Thoracic Surgeons risk calculator or the estimate of a surgeon coinvestigator following pre-specified protocol criteria, were enrolled. Results In the studies, 327 of 351 patients completed 12 months of follow-up. Patients were elderly (76 ± 11 years of age), with 70% having functional MR and 60% having prior cardiac surgery. The mitral valve device reduced MR to ≤2+ in 86% of patients at discharge (n = 325; p < 0.0001). Major adverse events at 30 days included death in 4.8%, myocardial infarction in 1.1%, and stroke in 2.6%. At 12 months, MR was ≤2+ in 84% of patients (n = 225; p < 0.0001). From baseline to 12 months, left ventricular (LV) end-diastolic volume improved from 161 ± 56 ml to 143 ± 53 ml (n = 203; p < 0.0001) and LV end-systolic volume improved from 87 ± 47 ml to 79 ± 44 ml (n = 202; p < 0.0001). New York Heart Association functional class improved from 82% in class III/IV at baseline to 83% in class I/II at 12 months (n = 234; p < 0.0001). The 36-item Short Form Health Survey physical and mental quality-of-life scores improved from baseline to 12 months (n = 191; p < 0.0001). Annual hospitalization rate for heart failure fell from 0.79% pre-procedure to 0.41% post-procedure (n = 338; p < 0.0001). Kaplan-Meier survival estimate at 12 months was 77.2%. Conclusions The percutaneous mitral valve device significantly reduced MR, improved clinical symptoms, and decreased LV dimensions at 12 months in this high-surgical-risk cohort. (Endovascular Valve Edge-to-Edge REpair STudy [EVERESTIIRCT]; NCT00209274)
    Journal of the American College of Cardiology 07/2014; 64(2):172–181. DOI:10.1016/j.jacc.2013.12.062 · 15.34 Impact Factor
  • European Heart Journal – Cardiovascular Imaging 03/2014; DOI:10.1093/ehjci/jeu049 · 2.65 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Many new devices and techniques are being developed to attempt a reduction in embolic stroke risk for patients with atrial fibrillation who are either unable or unwilling to maintain long-term anticoagulation. One of these new devices (LARIAT(®), SentreHEART Inc., Redwood City, California, USA) employs delivery of an epicardial suture to ligate the left atrial appendage after percutaneous pericardial and transseptal access. This series presents three clinical cases that demonstrate a serious and recurrent complication of left atrial laceration and cardiac tamponade shortly following delivery of an epicardial suture ligation to the left atrial appendage. Three clinical cases are described in detail with pre- and postprocedure angiography and echocardiography as well as illustrations reflecting the surgeon's findings on direct visualization of the left atrial lacerations postligation. Potential hypotheses of each injury are examined in light of the case timelines and findings at sternotomy. There was no suggestion that tamponade was related to pericardial or transseptal access, but rather a complication with device delivery. These three patients quickly progressed to clinical cardiac tamponade despite attempted drainage, stressing the importance of cardiovascular surgery backup, including a cardiopulmonary bypass pump, when delivering novel, percutaneous ligation devices for the left atrial appendage.
    11/2013; DOI:10.5761/atcs.cr.13-00134
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective To report the efficacy and safety of the Outback((R)) LTD (R) Re-Entry Catheter in reentering the distal true lumen during percutaneous intentional extraluminal revascularization (PIER). Background Reentry catheters are used to treat chronic, total arterial occlusions of the lower extremities when standard methods of recanalization have failed. Success and complication rates of these catheters in the real world are uncertain and variable. MethodsA retrospective review of our peripheral catheterization database from January 2004 to September 2009 was undertaken to identify consecutive cases of peripheral chronic total occlusions (CTOs) requiring the use of the Outback reentry catheter. Patient demographics, indication for the procedure, location and extent of occlusion, procedural success, and complications were studied. ResultsA total of 51 patients were identified. Of the 51, 28 (54.9%) patients presented with nonhealing ulcer and 22 (43.1%) had lifestyle-limiting claudication. One patient presented with acute limb ischemia. There were 6 (11.8%) patients with common iliac artery occlusion, 2 (3.9%) with external iliac artery occlusion, 1 (1.9%) with common femoral artery occlusion, 35 (68.6%) with superficial femoral artery occlusion, 6 (11.8%) with popliteal artery occlusion, and 1 (1.9%) with tibioperoneal artery occlusion. Median lesion length was 230 mm. Procedural success was achieved in 49 patients (96.1%). There was 1 (1.9%) periprocedural complication. Conclusion Use of Outback((R)) LTD (R) Re-Entry Catheter is a safe and valuable option for PIER/subintimal angioplasty and recanalization in patients with symptomatic lower-extremity CTOs. However, long-term patency remains unknown. (c) 2012 Wiley Periodicals, Inc.
    Catheterization and Cardiovascular Interventions 11/2013; 82(5). DOI:10.1002/ccd.22743 · 2.40 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: OBJECTIVES: We sought to evaluate 4-year outcomes of percutaneous repair versus surgery for mitral regurgitation. BACKGROUND: Transcatheter therapies are being developed to treat valvular heart disease. In the EVEREST II Trial, treatment of mitral valve regurgitation (MR) with a novel percutaneous device was compared with surgery and showed superior safety, but less reduction in MR at one year overall. We report the four year outcomes from the EVEREST II Trial. METHODS: Patients with grade 3+ or 4+ MR were randomly assigned to percutaneous repair with the MitraClip device or conventional mitral valve surgery in a 2:1 ratio (184:95). Patients were prospectively consented for five years of follow-up. RESULTS: At four years, the rate of the composite endpoint of freedom from death, surgery, or 3+ or 4+ MR in the intention to treat population was 39.8% vs. 53.4% in the percutaneous repair group and surgical groups, respectively (p=0.070). Rates of death were 17.4% vs. 17.8% (p=0.914), and 3+ or 4+ MR was present in 21.7% vs. 24.7% (p=0.745) at 4 years of follow-up, respectively. Surgery for mitral valve dysfunction, however, occurred in 20.4% vs. 2.2% (p<0.001) at one year and 24.8% vs. 5.5% (p<0.001) at four years. CONCLUSIONS: Patients treated with percutaneous repair of the mitral valve more commonly required surgery to treat residual MR; however, after the first year of follow-up, there were few surgeries required after either percutaneous or surgical treatment and no difference in the prevalence of moderate-severe and severe MR or mortality at four years.
    Journal of the American College of Cardiology 05/2013; 62(4). DOI:10.1016/j.jacc.2013.04.030 · 15.34 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: PURPOSE: To evaluate the performance of a heparin-bonded, expanded polytetrafluoroethylene (ePTFE)-lined nitinol endoprosthesis in the treatment of long-segment occlusive disease of the femoropopliteal artery (FPA) and to identify factors associated with loss of patency. MATERIALS AND METHODS: In a single-arm, prospective, 11-center study (VIPER [Gore Viabahn Endoprosthesis with Heparin Bioactive Surface in the Treatment of Superficial Femoral Artery Obstructive Disease] trial), 119 limbs (113 patients; 69 men; mean age, 67 y), including 88 with Rutherford category 3-5 disease and 72 with Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II) C or D lesions of the FPA, underwent stent graft implantation. The mean lesion length was 19 cm; 56% of lesions were occlusions. Follow-up evaluations included color duplex ultrasonography in all patients, with patency defined as a peak systolic velocity ratio< 2.5. RESULTS: At 12 months, Rutherford category and ankle-brachial index (ABI) were significantly improved (mean category improvement, 2.4; ABI increased from 0.6±0.2 to 0.9±0.19; P<.0001). Primary and secondary patency rates were 73% and 92%. The primary patency for devices oversized<20% at the proximal landing zone was 88%, whereas the primary patency for devices oversized by>20% was 70% (P = .047). Primary patency was not significantly affected by device diameter (5 vs 6 vs 7 mm) or lesion length (≤20 cm vs>20 cm). The 30-day major adverse event rate was 0.8%. CONCLUSIONS: The heparin-bonded, ePTFE/nitinol stent graft provided clinical improvement and a primary patency rate of 73% at 1 year in the treatment of long-segment FPA disease. Careful sizing of the device relative to vessel landing zones is essential for achieving optimal outcomes.
    Journal of vascular and interventional radiology: JVIR 02/2013; 24(2):165-173. DOI:10.1016/j.jvir.2012.10.004 · 2.15 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: SESSION TYPE: Heart FailurePRESENTED ON: Sunday, October 21, 2012 at 10:30 AM - 11:45 AMPURPOSE: Atrial septal defects (ASD) and patent foramen ovale (PFO) are the most common adult congenital heart disorders. A common indication for ASD closure is right ventricular enlargement. We report our experience with a cohort of patients who presented with unexplained shortness of breath and hypoxia.METHODS: We performed retrospective chart review of patients with ASD/PFO who presented with hypoxia or dyspnea on exertion and were referred to our pulmonary hypertension clinic from January 2010 to February 2012.RESULTS: We identified 15 patients (12 female), ages 15-78 (female mean age, 56; male mean age, 67). Seven patients (46.7%) had a tunnel PFO (four with right-to-left shunting, three with bidirectional shunting). Eight patients (53.3%) had ASD (one sinus venosus, seven secundum). Of the seven patients with a secundum ASD, five had left-to-right shunting and two had bidirectional shunting. Baseline functional status was NYHA Class IV in three patients (20%), Class III in 11 (73.3%) and Class II in one (6.7%). Five patients (33.3%) required continuous-flow oxygen. Five patients (33.3%) had severe pulmonary hypertension at diagnosis. Fourteen patients (93.3%) underwent percutaneous closure; one (6.7%) underwent surgical closure. All patients had improvement in NYHA class. Four out of five (80%) oxygen-dependant patients were taken off oxygen, and one had a decrease in oxygen requirement. All five pulmonary hypertension patients were weaned off associated medications. Follow-up echocardiography showed no evidence of residual shunts. One patient with syncope had complete resolution of her symptoms.CONCLUSIONS: There is a subset of patients with atrial level shunts who present with disproportionate hypoxia or shortness of breath. In these patients, careful evaluation should include a transesophageal echocardiography with saline contrast imaging and exercise hemodynamics. In our cohort, closure of the atrial shunt led to absolute resolution of their signs and symptoms, improvement in the NYHA class, decrease in oxygen requirements and resolution of pulmonary hypertension.CLINICAL IMPLICATIONS: Patients with atrial shunts and dyspnea require additional evaluations as they frequently can be cured by closure.DISCLOSURE: The following authors have nothing to disclose: Krishna Nagendran, Bijoy K. Khandheria, Tanvir Bajwa, Suhail Allaqaband, Mary E. Wenzel, A. Jamil Tajik, Dianne ZwickeNo Product/Research Disclosure InformationAurora Cardiovascular Services, Aurora Sinai/Aurora St. Luke's Medical Centers, University of Wisconsin School of Medicine and Public Health, Milwaukee, WI.
    Chest 10/2012; 142(4_MeetingAbstracts):81A. DOI:10.1378/chest.1384522 · 7.13 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Therapeutic hypothermia is currently used to reduce neurological ischemic damage in postcardiac arrest patients. Nevertheless, it has been associated with relevant side effects such as infections, bleeding, hypotension and hyperkalemia. Although hypothermia-induced coronary spasm is rare, its occurrence needs to be considered attentively as it adds a high risk of ventricular arrhythmias and cardiac arrest in patients with already-existing critical heart conditions. Copyright (c) 2012 S. Karger AG, Basel
    Cardiology 07/2012; 122(2):126-8. DOI:10.1159/000338805 · 2.04 Impact Factor
  • International journal of cardiology 07/2012; DOI:10.1016/j.ijcard.2012.06.083 · 6.18 Impact Factor
  • Journal of cardiothoracic and vascular anesthesia 05/2012; 26(5):e52-4. DOI:10.1053/j.jvca.2012.03.024 · 1.48 Impact Factor
  • 05/2012; 13(10):807. DOI:10.1093/ehjci/jes092
  • [Show abstract] [Hide abstract]
    ABSTRACT: We compared use of intravenous (IV) normal saline (NS) to sodium bicarbonate (NaHCO(3)) with or without oral N-acetylcysteine (NAC) for prevention of contrast-induced acute kidney injury (CI-AKI). CI-AKI is associated with significant adverse clinical events. Use of NAC has produced variable results. Recently, intravenous hydration with NaHCO(3) for CI-AKI prophylaxis has been adopted as standard treatment for patients with stable chronic renal disease undergoing catheterization procedures. We prospectively enrolled 320 patients with baseline renal insufficiency scheduled to undergo catheterization. Patients were randomly assigned to receive either IV NS ± NAC (n = 161) or IV dextrose 5% in water containing 154 mEq/l of NaHCO(3) ± NAC (n = 159). IV NS was administered at 1 ml/kg body weight for 12 hr preprocedure and 12 more hr postprocedure. IV NaHCO(3) was administered at 3 ml/kg body weight for 1 hr preprocedure followed by 1 ml/kg body weight postprocedure. A 1,200 mg oral dose of NAC was given 2-12 hr preprocedure and 6-12 hr postprocedure in 50% of patients in each study arm. CI-AKI was defined as an increase of >0.5 mg/dl or >25% above baseline creatinine. Overall incidence of CI-AKI was 10.3%. There was no significant difference in incidence among the two groups (NS ± NAC 11.8% vs. NaHCO(3) ± NAC 8.8%, p = ns). Incidence of CI-AKI increased with increasing age (p = 0.001), contrast agent use >3 ml/kg body weight (p = 0.038) and diuretic use (p = 0.005). Incidence of CI-AKI was no different in the NaHCO(3) group compared to NS group, and NAC did not reduce CI-AKI in the two study arms.
    Catheterization and Cardiovascular Interventions 05/2012; 79(6):929-37. DOI:10.1002/ccd.23148 · 2.40 Impact Factor
  • Journal of the American College of Cardiology 03/2012; 59(13 S-1):E214. DOI:10.1016/S0735-1097(12)60215-0 · 15.34 Impact Factor
  • Journal of the American College of Cardiology 03/2012; 59(13S-1):E256. DOI:10.1016/S0735-1097(12)60257-5 · 15.34 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In a push to treat ST-elevation myocardial infarction (STEMI) patients with primary percutaneous coronary intervention (PCI) within 90min of door-to-balloon time, emergency cardiac catheterization laboratory activation protocols bypass routine clinical assessments, raising the possibility of more frequent catheterizations in patients with no culprit coronary lesion. To determine the incidence, predictors, and prognosis of false-positive STEMI. We followed a prospective cohort of patients diagnosed with STEMI by usual criteria receiving emergency cardiac catheterization with intention of primary PCI between January 2005 and December 2007 at a tertiary care center. False-positive STEMI was defined as absence of a clear culprit lesion on coronary angiography. Of 489 patients who received emergency cardiac catheterization indicated for STEMI, 54 (11.0%, 95% confidence interval [CI] 8.3-13.8) had no culprit lesion on coronary angiography. Independent predictors of false-positive STEMI were absence of chest pain (odds ratio [OR] 18.2, 95% CI 3.7-90.1), no reciprocal ST-segment changes (OR 11.8, 95% CI 5.14-27.3), fewer than three cardiovascular risk factors (OR 9.79, 95% CI 4.0-23.8), and symptom duration longer than 6h (OR 9.2, 95% CI 3.6-23.7); all p<0.001. Using predictors, we modeled a risk score that achieved 88% (95% CI 81-94%) accuracy in identifying patients with negative coronary angiography. Among the false-positive STEMI patients, 48.1% had other serious diagnoses related to their electrocardiographic findings. When the diagnosis of STEMI is in doubt, clinicians may use predictors to quickly reassess the likelihood of an alternative diagnosis.
    Journal of Emergency Medicine 01/2012; 43(4):561-7. DOI:10.1016/j.jemermed.2011.09.027 · 1.18 Impact Factor

Publication Stats

2k Citations
511.22 Total Impact Points


  • 2004–2015
    • Aurora St. Luke's Medical Center
      Milwaukee, Wisconsin, United States
    • St. Mary's Hospital (WI, USA)
      Madison, Wisconsin, United States
  • 1994–2014
    • University of Wisconsin - Milwaukee
      • College of Health Sciences
      Milwaukee, Wisconsin, United States
  • 2013
    • Aurora Health Care
      Milwaukee, Wisconsin, United States
  • 2008
    • Milwaukee Institute of Art & Design
      Milwaukee, Wisconsin, United States
  • 1994–2007
    • Samaritan Medical Center
      Watertown, New York, United States
  • 1996
    • University of Texas Medical Branch at Galveston
      Galveston, Texas, United States